

***Fiscal Year 2026 Department of Defense
Lupus Research Program (LRP)
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|---|---|---|
| <p>Idea Award (IA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526LRPIA</p> | <p>Independent investigators and mentored investigators who have received their terminal degree (e.g., postdoctoral fellows or equivalent)</p> | <ul style="list-style-type: none"> • Supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. • Research must address one of the FY26 LRP IA Focus Areas. • Emphasis is on innovation. • Preliminary data are not required. • <i>Clinical trials are not allowed.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. | <p>Pre-Application (Letter of Intent): July 29, 2026 5:00 p.m. Eastern time</p> <p>Application: August 19, 2026 11:59 p.m. Eastern time</p> |
| <p>Impact Award (IPA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526LRPIPA</p> | <p>Independent investigators or equivalent</p> | <ul style="list-style-type: none"> • Supports high-risk/high-reward research that has the potential to make a major impact in lupus research and/or lupus disease. • Research must address one of the FY26 LRP IPA Focus Areas. • Emphasis is on impact. • Preliminary data are encouraged but not required. • <i>Clinical trials are not allowed.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1 million (M) for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Letter of Intent): July 29, 2026 5:00 p.m. Eastern time</p> <p>Application: August 19, 2026 11:59 p.m. Eastern time</p> |
| <p>Transformative Vision Development Award (TVDA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526LRPTVDA</p> | <p>Independent investigators or equivalent</p> | <ul style="list-style-type: none"> • Supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. • Research must address one of the FY26 LRP TVDA Focus Areas. • Preliminary data are permitted but not required. • <i>Human subject research and phase 0/1 clinical trials are allowed. Phase 2/3 clinical trials are not allowed.</i> • <i>Animal studies are not allowed.</i> • <i>The research team must include one or more lupus consumer advocate(s).</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$250,000 for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. | <p>Pre-Application (Letter of Intent): July 29, 2026 5:00 p.m. Eastern time</p> <p>Application: August 19, 2026 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|---|--|---|
| <p>Transformative Vision Award (TVA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526LRPTVA</p> | <p>Independent investigators or equivalent</p> | <ul style="list-style-type: none"> • Supports interventional research at the individual and/or health care system level, which will result in near-term impact on the health-related quality of life of persons living with lupus. • Research must address one of the FY26 LRP TVA Focus Areas. • Emphasis is on near-term impact on quality of life. • Human subject research and clinical trials are allowed. • <i>Preliminary data are required.</i> • <i>Animal studies are not allowed.</i> • Partnering Principal Investigator (PI) Option allows one Initiating Investigator and a maximum of two Partnering PIs. • <i>The research team must include one or more lupus consumer advocate(s).</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2M for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Letter of Intent): July 29, 2026 5:00 p.m. Eastern time</p> <p>Application: August 19, 2026 11:59 p.m. Eastern time</p> |